Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Opioid-induced Hyperalgesia
NCT04059978Completed
- Sponsor
- University Hospital Basel
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in opioid-induced hyperalgesia (OIH) comparing CBD + Remifentanil with Placebo + Remifentanil (2 arms). Primary endpoint: Area Under the Curve for Hyperalgesia. Started May 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
opioid-induced hyperalgesia (OIH)
Beyond the preview
Go deeper on NCT04059978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059978.